Ostarine vs LGD-4033: Which SARM Actually Works and What Are the Real Risks?

What Are Ostarine and LGD-4033?

Ostarine and LGD-4033 are nonsteroidal compounds that bind the androgen receptor with high selectivity. The goal during their original development was to capture the muscle-preserving effects of androgens without the prostate, scalp, and cardiovascular liabilities tied to testosterone or classic anabolic steroids. Neither compound has completed Phase III trials or received FDA approval for any indication.

Ostarine (MK-2866, enobosarm) was developed by GTx Inc. and later Mereo BioPharma. It reached Phase II and Phase III trials for cancer-related muscle wasting and stress urinary incontinence before late-stage development stalled. LGD-4033 (ligandrol, VK5211) was developed by Ligand Pharmaceuticals and acquired by Viking Therapeutics, where it has been studied under the name VK5211 for hip fracture recovery. Both compounds are sold openly as "research chemicals" online, and both have a well-documented gap between the doses used in clinical studies and the doses found in real-world use.

The FDA issued a safety warning in October 2017 specifically naming SARMs, stating that these products are not dietary supplements and that they carry serious safety concerns, including the potential to increase the risk of heart attack and stroke [1]. That warning has not been rescinded.

How Do Their Mechanisms Differ?

Both compounds act as partial-to-full agonists at the androgen receptor in skeletal muscle and bone while showing tissue-selective activity compared to testosterone. The selectivity claim is accurate in animal models but is more complicated in humans.

Ostarine shows a tissue-selectivity ratio (anabolic to androgenic) estimated at roughly 3:1 in preclinical work, meaning it produces measurable anabolic effects at doses that cause comparatively less androgenic activity in prostate tissue [2]. LGD-4033 binds the androgen receptor with higher affinity than ostarine and is considered a full agonist in muscle tissue. This higher affinity explains both its greater anabolic potency per milligram and its steeper suppression of the hypothalamic-pituitary-gonadal axis at clinical doses.

Neither compound is a progestogen or estrogen, so direct estrogenic side effects are not expected from the parent molecule. However, because both suppress endogenous testosterone, aromatization of endogenous T drops, and some users report low-estrogen symptoms during and after a cycle.

What Does the Clinical Evidence Show for Lean Mass?

The evidence base is thin compared to approved drugs, but it exists. For LGD-4033, the key Phase I trial published in the Journals of Gerontology (Basaria et al., 2013, N=76 healthy men) remains the most-cited dataset. Participants received 0.1, 0.3, or 1 mg/day for 21 days. At the 1 mg dose, lean body mass increased by a statistically significant 1.21 kg compared to placebo (P<0.001), while fat mass did not change significantly [3]. Stair-climbing power improved as well. The 21-day duration is short, and the study was not powered to assess long-term safety endpoints.

For ostarine, a Phase II trial in older men and postmenopausal women (Dalton et al., 2011, N=120) tested 1 mg and 3 mg doses over 12 weeks. Both doses produced statistically significant increases in lean mass and improvements in physical function scores. The 3 mg group gained approximately 1.4 kg of lean mass on average, and stair-climb power rose by roughly 15.8% compared to baseline [4]. This trial ran six times longer than the LGD-4033 Phase I, giving a better safety window to examine.

No head-to-head randomized controlled trial has directly compared ostarine and LGD-4033 in the same study population. Any comparison made here or elsewhere is therefore cross-trial inference, and should be read with that caveat clearly in mind.

HealthRX Clinical Comparison Framework: Ostarine vs LGD-4033

| Parameter | Ostarine (MK-2866) | LGD-4033 | |---|---|---| | Highest clinical dose | 3 mg/day (Phase II) | 1 mg/day (Phase I) | | Lean mass change (clinical) | +1.4 kg at 12 weeks (3 mg) | +1.21 kg at 21 days (1 mg) | | Testosterone suppression | Mild at doses <3 mg; notable at illicit doses | Dose-dependent, significant at 1 mg | | SHBG suppression | Modest | Marked (useful for free-T estimation) | | Half-life | ~24 hours | ~24-36 hours | | Published DILI cases | Yes | Yes | | WADA ban | Yes (S1 list) | Yes (S1 list) | | Phase of development | Phase III attempted | Phase II (hip fracture) |

Testosterone Suppression: The Most Clinically Significant Difference

Testosterone suppression is the area where the two compounds diverge most meaningfully in clinical data. In the Basaria et al. LGD-4033 trial, free testosterone fell significantly at all three doses, and sex hormone-binding globulin (SHBG) fell in a dose-dependent manner [3]. Total testosterone suppression at 1 mg/day was substantial enough that the authors noted the need for monitoring if LGD-4033 were to be used longer-term or at higher doses.

Ostarine at 1 to 3 mg/day showed less dramatic suppression in the Dalton trial, though free testosterone did decrease, particularly in men. The lower androgenic potency of ostarine per milligram appears to translate directly into less HPG axis feedback inhibition at equivalent therapeutic doses.

Where this becomes a practical problem is illicit use. Community-reported doses of LGD-4033 commonly run 5 to 10 mg/day for 8, 12-week cycles, five to ten times higher than any Phase I dose. At those exposures, total testosterone can fall into hypogonadal ranges (<300 ng/dL) during and after the cycle, requiring weeks to months for recovery. A case series published in the Annals of Internal Medicine (Flores et al., 2020) documented patients presenting with symptomatic hypogonadism and elevated liver enzymes after using LGD-4033 at doses sourced online [5]. Several required short-term testosterone support before natural recovery.

Ostarine at illicit doses (10 to 25 mg/day) can produce a similar, though generally less severe, suppression pattern. Post-cycle testosterone recovery appears faster for ostarine in anecdotal reports, though no randomized data confirm this.

Liver Safety: Both Carry Real Risk

The "selective" label in SARM does not indicate liver safety. Multiple published case reports document drug-induced liver injury from both compounds.

A 2022 case report in ACG Case Reports Journal described a 32-year-old man who developed cholestatic hepatitis after an 8-week cycle of ostarine at 20 mg/day, with alanine aminotransferase peaking above 1 to 000 U/L and bilirubin rising to 14 mg/dL. Liver biopsy confirmed cholestatic injury. He recovered fully over approximately 3 months after stopping the compound [6].

LGD-4033 carries a similar pattern. The previously cited Flores case series included patients with bilirubin elevations and transaminases in the hundreds. Both compounds appear capable of causing cholestatic liver injury, likely through androgen receptor-mediated effects on bile acid transport rather than direct cytotoxicity, though the exact mechanism is not fully resolved.

The practical message: liver function testing (ALT, AST, total and direct bilirubin, ALP) before and during SARM use is not optional if someone is going to use these compounds. Any ALT rise above three times the upper limit of normal warrants immediate cessation.

SARMs vs Anabolic Steroids: How Do Ostarine and LGD-4033 Compare?

The comparison between SARMs and traditional anabolic-androgenic steroids (AAS) like testosterone, nandrolone, or oxandrolone is instructive for understanding where SARMs sit on the risk-benefit spectrum.

Anabolic steroids are steroidal androgens. They bind the androgen receptor but also interact with other steroid receptors and undergo significant hepatic and peripheral metabolism. Orally active 17-alpha-alkylated AAS (like oxandrolone/Anavar) are well-documented hepatotoxins. Injectable testosterone and its esters are not hepatotoxic at replacement doses but suppress HPG axis function completely during administration.

SARMs were designed to achieve a cleaner separation between anabolic and androgenic activity. In clinical trials at low doses, they largely achieve this. At the doses common in recreational bodybuilding, the separation narrows. LGD-4033 at 10 mg/day likely produces androgenic and suppressive effects approaching those of a moderate testosterone dose, without the decades of safety data that accompany medically supervised testosterone.

A direct comparison relevant to the secondary query "anavar vs ostarine": oxandrolone (Anavar) at 20 mg/day in clinical trials produces lean mass gains of approximately 2 to 3 kg over 12 weeks in older adults, larger than ostarine at 3 mg/day [7]. Oxandrolone is an FDA-approved drug with defined pharmacokinetics, known drug interactions, and a regulated manufacturing process. Ostarine sourced online has been found in independent lab testing to vary from 0% to 150% of labeled dose, with frequent contamination.

The Endocrine Society's 2020 position statement on SARMs states: "At this time, we do not have sufficient evidence that the risks associated with SARMs are acceptable, and we are concerned that some members of the public may be misled to believe that these compounds are safe" [8]. That position has not changed in subsequent updates.

Cardarine and Clenbuterol: Two More Compounds Often Compared

Users researching ostarine and LGD-4033 often encounter cardarine (GW501516) and clenbuterol. Brief clarity on both is warranted.

Cardarine is not a SARM. It is a PPARdelta agonist. GlaxoSmithKline terminated its development program after cardarine caused rapid dose-dependent carcinogenesis in multiple organ systems in rodent studies at doses not far above those proposed for human use. No human trials were completed. WADA banned it in 2009. There is no safe dose established for humans, and comparing it to ostarine or LGD-4033 as though they sit on the same risk tier is incorrect.

Clenbuterol is a beta-2 adrenergic agonist approved in some countries as a bronchodilator for horses and, in a small number of countries, for human asthma management. It is not approved for weight loss or fat burning in the United States. At doses used illicitly for fat loss (80 to 160 mcg/day), clenbuterol produces cardiac hypertrophy, tachycardia, hypokalemia, and has been linked to fatal arrhythmias [9]. A 2021 FDA advisory note reiterated that clenbuterol is not approved for human use in the US and that products containing it are subject to enforcement action.

Neither cardarine nor clenbuterol offers a safer or more evidence-backed option than ostarine or LGD-4033. In terms of risk, cardarine likely sits in a higher-concern category than either SARM given the carcinogenesis findings.

What Happens After the Cycle? Recovery and Monitoring

HPG axis recovery after stopping SARMs is the most clinically underdocumented area because no sponsor has funded long-term post-cycle studies. Based on the pharmacokinetic half-lives (ostarine ~24 hours; LGD-4033 ~24 to 36 hours), both compounds clear within 5 to 7 days. Androgen receptor occupancy falls accordingly, but HPG axis recovery lags behind clearance.

In the Basaria Phase I trial, LGD-4033 users' testosterone levels returned to near-baseline within 5 weeks of stopping 1 mg/day for 21 days [3]. Real-world users running 10 mg/day for 12 weeks report recovery timelines of 8 to 16 weeks, with a subset requiring longer, but these figures come from online self-report forums rather than controlled studies.

Some practitioners apply post-cycle therapy (PCT) protocols borrowed from anabolic steroid use, typically a 4-week course of clomiphene 25 to 50 mg/day or tamoxifen 20 mg/day, to accelerate HPG axis recovery. No randomized trial has tested this specifically for SARMs. The American Urological Association's 2018 testosterone deficiency guideline notes that clomiphene can raise LH and FSH and is sometimes used off-label to stimulate endogenous testosterone production, which provides a pharmacological rationale even in the absence of SARM-specific data [10].

Any man completing a SARM cycle should obtain a morning total testosterone, LH, FSH, and complete metabolic panel (including liver enzymes) at the end of the cycle and again 6 to 8 weeks later to confirm recovery.

Who Is Researching These Compounds Clinically?

Despite the lack of approved indications, legitimate pharmaceutical development continues. Viking Therapeutics reported Phase II data for VK5211 (LGD-4033) in hip fracture rehabilitation in 2017, showing statistically significant improvements in lean mass and appendicular lean mass versus placebo over 12 weeks, with a safety profile described as generally clean at the doses studied [11]. The company has not yet published a Phase III readout.

Ostarine's development for cancer cachexia was halted after a Phase III trial (POWER 1 and POWER 2) failed to meet primary endpoints in non-small cell lung cancer patients [12]. The failure was not attributed to safety signals but to lack of efficacy at the doses tested in that population.

The gap between pharmaceutical development and illicit use is wide. Pharmaceutical doses prioritize safety margins. Illicit doses prioritize visible body composition change on a 10, 12-week cycle. Those goals are not the same, and the evidence supporting one does not support the other.

Practical Guidance for Clinicians Seeing SARM Users

Patients who have used SARMs and present with fatigue, low libido, or depressed mood in the weeks following a cycle are likely experiencing secondary hypogonadism from HPG axis suppression. The correct initial workup is a morning total testosterone, free testosterone (or calculated free T from SHBG), LH, FSH, and a hepatic panel.

If total testosterone is below 300 ng/dL with suppressed LH and FSH, the diagnosis is consistent with drug-induced secondary hypogonadism. Management options include watchful waiting with repeat labs at 6 to 8 weeks, off-label clomiphene to stimulate recovery, or short-term testosterone therapy in severe cases while waiting for recovery. Starting long-term TRT in a young man with drug-induced secondary hypogonadism before giving the axis time to recover is generally not appropriate unless 6 months of follow-up demonstrates no recovery.

If liver enzymes are elevated, discontinue any remaining SARM use, order a hepatitis panel to rule out viral causes, and obtain a right upper quadrant ultrasound. A hepatology referral is appropriate for bilirubin above 2 mg/dL or ALT above 500 U/L.

The Endocrine Society recommends against prescribing or recommending SARMs to patients outside of an IRB-approved clinical trial, and this is the standard the HealthRX medical team follows [8]. The practical role of the clinician here is detection, monitoring, and recovery support, not prescription of these compounds.

Dosing, Detection, and Regulatory Status

Both ostarine and LGD-4033 are detectable by WADA-accredited anti-doping laboratories using urine and blood mass spectrometry panels for periods of 2 to 4 weeks after the last dose for most standard testing protocols, though metabolites can extend detection windows. Both compounds are on WADA's Prohibited List under S1.2 (other anabolic agents) [13].

In the United States, they are not scheduled controlled substances under the Controlled Substances Act as of this writing, but they are not legal dietary supplement ingredients, cannot be sold as supplements, and cannot be legally prescribed because they hold no approved New Drug Application. The Drug Enforcement Administration has the authority to schedule SARMs, and legislation to do so has been introduced in Congress (SARMS Control Act of 2019), though as of early 2025 that legislation has not been enacted.

Manufacturers selling SARMs as research chemicals occupy a legal gray area that the FDA has explicitly stated does not protect them from enforcement action if the products are marketed with implied human use claims [1].